Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Gentamicin sulfate 0.3%, dexamethasone Na phosphate 0.1%
Indication
Eye: Bacterial conjunctivitis, blepharoconjunctivitis, keratoconjunctivitis, non-specific keratitis, deep keratitis, corneal ulcer, and scleritis, acute and chronic nonpurulent conjunctivitis.
Instruction
Drops: Instill 1 drop 4-6 times daily into the affected eye. Unscrew the cap covering the nozzle. With a finger, retract the lower eyelid until the inner red, moist surface is exposed. Tilt head back, invert the bottle and gently squeeze out the prescribed number of drops onto the exposed surface of the lower lid avoiding any contact of the bottle with eye or skin. Close the bottle carefully after use.
Drug interaction
Aminoglutethimide: May lead to loss of prednisolone-induced adrenal suppression. Amphotericin B: Coadministration may be followed by cardiac enlargement and CHF. Anticholinesterase agents: Coadministration may produce severe weakness in patients with myasthenia gravis. If possible, withdraw anticholinesterase agent 24 h prior to starting prednisolone. Antidiabetic agents: Because prednisolone may increase blood glucose concentrations, dose adjustments of antidiabetic agents may be required. Aspirin and other salicylates, NSAIDs: Risk of GI bleeding may be increased. Salicylate clearance may be increased. CYP3A4 inducers (eg, barbiturates, carbamazepine, phenytoin, rifampin). Prednisolone metabolism may be increased, reducing prednisolone plasma levels and necessitating an increase in dosage. CYP3A4 inhibitors (eg, estrogens [eg, hormonal contraceptives], ketoconazole, macrolide antibiotics [eg, erythromycin]) Prednisolone metabolism may be decreased, increasing prednisolone plasma levels and increasing the risk of adverse reactions. Cholestyramine: Prednisolone clearance may be increased, reducing plasma levels and decreasing the efficacy. Cyclosporine: Increased activity of cyclosporine and prednisolone may occur. Convulsions have been reported with coadministration of corticosteroids and cyclosporine. Digitalis glycosides: Because of possible hypokalemia, the risk of arrhythmias may be increased. Isoniazid: Isoniazid serum levels may be reduced, decreasing the efficacy. Potassium-depleting agents (eg, amphotericin B, diuretics): Risk of hypokalemia may be increased.Toxoids and live or inactivated vaccines: Because of inhibition of antibody response, patients on prolonged prednisolone therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Replication of some organisms contained in live attenuated vaccines may be potentiated. Warfarin: Because data are conflicting, monitor coagulation indices frequently.
Malaysia
